trustnet

Mereo BioPharma Grp

Director/PDMR Shareholding
RNS Number : 0440A
Mereo BioPharma Group plc
23 May 2019
 

 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Notification of PDMR and Director Dealing

 

 

London, May 23, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on May 21, 2019, Peter Bains, Director of Mereo, purchased 47,500 ordinary shares at a price of GBP0.90 per share. Peter also purchased 778 American Depositary Shares (ADSs) at a price of USD4.92 per share.

 

In addition, on May 22, 2019, John Richard, Head of Corporate Development at Mereo, purchased 3000 ADSs at a price of USD4.90 per share.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

a)

Name

Peter Bains

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

GBP0.90

47,500

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 47,500

Aggregated price: GBP0.90

e)

Date of the transaction

2019-05-21

f)

Place of the transaction

AIMX

 

1

Details of the person discharging managerial responsibilities

a)

Name

Peter Bains

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

PURCHASE of ADS

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD4.92

778

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 778

Aggregated price: USD4.92

e)

Date of the transaction

2019-05-21

f)

Place of the transaction

XNMS

 

 

 

1

Details of the person discharging managerial responsibilities

a)

Name

John Richard

2

Reason for the notification

a)

Position/status

Head of Corporate Development

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

PURCHASE of ADS

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD4.90

3000

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 3000

Aggregated price: USD4.903

e)

Date of the transaction

2019-05-22

f)

Place of the transaction

XNMS

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEXLFLKEFBBBD